What the changes say
- Shuttle Pharmaceuticals added risks related to its Molecule.ai acquisition and ongoing Nasdaq listing compliance issues involving stockholders equity and bid price.
- The company dropped 36 general development and clinical trial risks.
What changed since the prior 10-K
New
- NewRisks Related to Our Business, Financial Condition and Capital Requirements
Recent and future acquisitions may have a material adverse effect on our ability to manage our business and our results of operations and financial condition
Acquiring assets like Molecule.ai from 1563868 B.C. Ltd. and integrating new personnel like Zhitian Zhang may disrupt operations and fail to deliver intended benefits.
- NewRisks Related to Our Business, Financial Condition and Capital Requirements
If we are unable to acquire and retain customers for our Molecule.ai platform or if any of such customers renew licenses at lower prices, our future revenues may be negatively impacted
The Molecule.ai platform currently has no customers, and failure to secure and renew software license agreements at profitable prices will hurt future revenues.
- NewRisks Related to our Common Stock
Following the March 2025 $5.75 million equity financing, on March 14, 2025, Nasdaq acknowledged that we had regained compliance with the Listing Rule 5550(b)(1) but indicated that if we failed to evidence compliance upon filing the March 31, 2025 Form 10-Q, we may have been subject to delisting
A 1-for-25 reverse stock split was executed on June 16, 2025, to satisfy Nasdaq minimum bid price requirements of $1.00 per share.
- NewRisks Related to our Common Stock
On July 2, 2025, we received notification from Nasdaq acknowledging that we maintained the requisite minimum closing bid price of our common stock of $1.00 per share or greater. Accordingly, we regained compliance with Listing Rule 5550(a)(2), and the matter was closed
Deficits in stockholders equity led to compliance issues, addressed through a November 2025 private placement raising $2.5 million and a March 2026 offering raising $3.5 million.
Dropped
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Our success is primarily dependent on the successful development, regulatory approval and commercialization of our product candidates, all of which are in the early stages of development
Product candidates like Ropidoxuridine, HDAC inhibitors, PC-RAD, and PSMA-B are in early development.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
We currently have no source of product sales revenue
The company has no product sales revenue.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
The market may not be receptive to our product candidates based on our novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates
The market may reject novel radiation sensitization therapeutic approaches.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
Raising additional capital may cause dilution.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Unfavorable and/or unstable global market and economic conditions, including those caused by the ongoing conflict between the Ukraine and Russia, as well as in the Middle East, and the COVID-19 pandemic, could have serious adverse consequences on our business, financial condition and results of operations
Unfavorable global market conditions from Ukraine-Russia conflict, Middle East, and COVID-19 pandemic.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Our product candidates are in the early stages of development and may fail in development or suffer delays that materially adversely affect their commercial viability
Early stage product candidates may fail or suffer clinical development delays.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Because we rely on third party manufacturing and supply partners, our supply of research and development, and preclinical and clinical development materials, may become limited or interrupted or may not be of satisfactory quantity or quality
Reliance on third-party manufacturing and supply partners for research and clinical materials.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
We may be unsuccessful in engaging in strategic transactions which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management
Unsuccessful strategic transactions or collaborations.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan
Dependence on key executives including Anatoly Dritschilo, Timothy Lorber, and Mira Jung.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
If our product candidates advance into Phase II and Phase III clinical trials, we may experience difficulties in managing our growth and expanding our operations
Difficulties managing growth during Phase II and Phase III clinical trials.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business
Failure to comply with U.S. and foreign regulatory requirements.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material effect on our business, financial condition, results of operations or prospects
Significant product liability risks and insufficient insurance coverage.
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Our proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Our information technology systems could face serious disruptions that could adversely affect our business
- DroppedRisks Related to Our Business, Financial Condition and Capital Requirements
Changes in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change our compensation policies
- DroppedRisks Related to Our Intellectual Property
If we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization of our product candidates may be adversely affected
- DroppedRisks Related to Our Intellectual Property
We may decide for business reasons to no longer pursue or to abandon certain intellectual property rights in the U.S. or elsewhere, including due to non-cooperation of inventors or owners of such intellectual property, prior art, or scope of protection, or for other reasons
- DroppedRisks Related to Our Intellectual Property
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
- DroppedRisks Related to Our Intellectual Property
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
- DroppedRisks Related to Government Regulation and Product Approvals
We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates
- DroppedRisks Related to Government Regulation and Product Approvals
If we or our collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation
- DroppedRisks Related to Government Regulation and Product Approvals
Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which may harm our business
- DroppedRisks Related to Government Regulation and Product Approvals
Our ability to obtain services, reimbursement or funding from the federal government, including the ability to obtain grants from the NIH, may be impacted by possible reductions in federal spending or changes in regulations or the regulatory environment
- DroppedRisks Related to Government Regulation and Product Approvals
If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product candidate, our ability to market and derive revenue from the product candidates could be compromised
- DroppedRisks Related to our Common Stock
Nasdaq’s notice has no immediate effect on the listing of the Company’s securities on the Nasdaq Capital Market. Nasdaq provided the Company with 45 calendar days, or until October 25, 2024, to submit a plan to regain compliance with the minimum stockholders’ equity standard
- DroppedRisks Related to our Common Stock
Under the Jobs Act, the information that we will be required to disclose has been reduced in a number of ways
- DroppedRisks Related to our Common Stock
If we fail to maintain applicable listing requirements, Nasdaq may delist our common stock from trading, in which case the liquidity and market price of our common stock could decline
- DroppedRisks Related to our Common Stock
Because our management has broad discretion over the use of the net proceeds we have received, or will receive, from our equity and/or debt follow-on offerings, you may not agree with how we use them and the proceeds may not be invested successfully
- DroppedRisks Related to our Common Stock
The ability of our executive officers and directors, who are our principal stockholders, to control our business may limit or eliminate the ability of minority stockholders to influence corporate affairs
- DroppedRisks Related to our Common Stock
The restatement of our consolidated financial statements and identification of material weaknesses in our internal controls may result in additional risks and uncertainties, including regulatory, stockholder or other actions, loss of investor and counterparty confidence and negative impacts on our stock price
- DroppedRisks Related to our Common Stock
If we fail to comply with the continued listing requirements of Nasdaq, it could result in our common stock being delisted, which could adversely affect the market price and liquidity of our securities and could have other adverse effects
- DroppedRisks Related to our Common Stock
Sales of substantial amounts of our securities in the public market could depress the market price of our common stock
- DroppedRisks Related to our Common Stock
Our securities may experience extreme price and volume fluctuations, which could lead to costly litigation for us and make an investment in us less appealing
Reworded
- 79% rewrittenRisks Related to our Common Stock
If we fail to comply with the continued listing requirements of The Nasdaq Stock Market, it could result in our common stock being delisted, which could adversely affect the market price and liquidity of our securities and could have other adverse effects
Added specific disclosures regarding the failure to maintain the Stockholders Equity Requirement under Nasdaq Listing Rule 5550(b)(1) alongside the minimum bid price deficit.
- 74% rewrittenRisks Related to our Common Stock
FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our securities
Retained SEC Regulation Best Interest and FINRA sales practice requirements language without substantive changes to the core risk.
- 45% rewrittenRisks Related to our Common Stock
Our board of directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to holders of our common stock and such issuance could potentially adversely affect stockholders’ voting power and perpetuate their control over us
Retained preferred stock issuance authority language without substantive changes to the governance risk.
- 22% rewrittenRisks Related to our Common Stock
Provisions in our amended and restated certificate of incorporation, as amended, and bylaws, as amended, as well as Delaware law, might discourage, delay or prevent a change of control of our company or changes in our management and, therefore, depress the market price of our common stock
Retained anti-takeover provisions and Delaware law restrictions language without substantive changes.
All 17 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Business, Financial Condition and Capital Requirements
- 01Recent and future acquisitions may have a material adverse effect on our ability to manage our business and our results of operations and financial conditionNew
- 02If we are unable to acquire and retain customers for our Molecule.ai platform or if any of such customers renew licenses at lower prices, our future revenues may be negatively impactedNew
- 03While our Company’s management is working to improve our internal controls and procedures, at present management has determined that our internal controls were deemed to be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public
- 04Failure of our information technology systems could significantly disrupt the operation of our business
Risks Related to our Common Stock
- 05If we fail to comply with the continued listing requirements of The Nasdaq Stock Market, it could result in our common stock being delisted, which could adversely affect the market price and liquidity of our securities and could have other adverse effects79% rewritten
- 06Following the March 2025 $5.75 million equity financing, on March 14, 2025, Nasdaq acknowledged that we had regained compliance with the Listing Rule 5550(b)(1) but indicated that if we failed to evidence compliance upon filing the March 31, 2025 Form 10-Q, we may have been subject to delistingNew
- 07On July 2, 2025, we received notification from Nasdaq acknowledging that we maintained the requisite minimum closing bid price of our common stock of $1.00 per share or greater. Accordingly, we regained compliance with Listing Rule 5550(a)(2), and the matter was closedNew
- 08Our stock price may be volatile, and purchasers of our common stock could incur substantial losses
- 09The future issuance of equity or of debt securities that are convertible into common stock will dilute our share capital
- 10If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline
- 11Our board of directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to holders of our common stock and such issuance could potentially adversely affect stockholders’ voting power and perpetuate their control over us45% rewritten
- 12Our Certificate of Incorporation, as amended to date, provides that disputes must be resolved in the Court of Chancery of the State of Delaware, except for cases brought under the Securities Act or Exchange Act
- 13We do not expect to pay cash dividends in the foreseeable future
- 14Provisions in our amended and restated certificate of incorporation, as amended, and bylaws, as amended, as well as Delaware law, might discourage, delay or prevent a change of control of our company or changes in our management and, therefore, depress the market price of our common stock22% rewritten
- 15Although we have no preferred stock outstanding as of the date hereof and we have currently no intention to issue any preferred stock, our common stockholders could be adversely affected by the issuance by us of preferred stock in the future, if any
- 16Trading of our common stock may be limited, making it difficult for our stockholders to sell their shares, and future sales of common stock could reduce our stock price
- 17FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our securities74% rewritten
Other Shuttle Pharmaceuticals Holdings 10-Ks
- FY2024 10-K risk factors49 risks
Shuttle Pharmaceuticals has no commercial revenue and depends on developing early-stage candidates like Ropidoxuridine and HDAC inhibitors.
Filed Feb 26, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.